Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. Semin Immunol. 2021;51:101471. https://doi.org/10.1016/j.smim.2021.101471.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomas A, Hammarlund E, Gao L, Holman S, Michel KG, Glesby M, et al. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy. J Infect Dis. 2019;222(2):243–51. https://doi.org/10.1093/infdis/jiz678.

Article  CAS  PubMed Central  Google Scholar 

Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571–9. https://doi.org/10.1182/blood-2010-05-285528.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abudulai LN, Fernandez S, Corscadden K, Hunter M, Kirkham LA, Post JJ, et al. Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016;71(4):381–9. https://doi.org/10.1097/qai.0000000000000869.

Article  CAS  PubMed  Google Scholar 

Van de Wijer L, van der Heijden WA, Ter Horst R, Jaeger M, Trypsteen W, Rutsaert S, et al. The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial Translocation. Front Immunol. 2021;12:661990. https://doi.org/10.3389/fimmu.2021.661990.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyd MA, van Bockel D, Munier CML, Kelleher AD. Navigating the complexity of chronic HIV-1 associated immune dysregulation. Curr Opin Immunol. 2022;76:102186. https://doi.org/10.1016/j.coi.2022.102186.

Article  CAS  PubMed  Google Scholar 

Mercurio V, Fitzgerald W, Vanpouille C, Molodtsov I, Margolis L. Mechanisms of residual immune activation in HIV-1-infected human lymphoid tissue ex vivo. AIDS. 2021;35(8):1179–90. https://doi.org/10.1097/qad.0000000000002881.

Article  CAS  PubMed  Google Scholar 

Ruperto LR, Arenzana CB, Marhuenda AR, Bernardino JI. Chapter 7 - Autoimmunity and HIV infection. In: Rezaei N, editor. Translational Autoimmunity. Academic Press; 2022. p. 141–67.

Chapter  Google Scholar 

Garcia Garrido HM, Mak AMR, Wit F, Wong GWM, Knol MJ, Vollaard A, et al. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting. Clin Infect Dis. 2020;71(1):41–50. https://doi.org/10.1093/cid/ciz728.

Article  PubMed  Google Scholar 

Erdmann NB, Prentice HA, Bansal A, Wiener HW, Burkholder G, Shrestha S, et al. Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. Front Public Health. 2018;6:70. https://doi.org/10.3389/fpubh.2018.00070.

Article  PubMed  PubMed Central  Google Scholar 

Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130–9. https://doi.org/10.1093/cid/cit937.

Article  CAS  PubMed  Google Scholar 

El Chaer F, El Sahly HM. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am J Med. 2019;132(4):437–46. https://doi.org/10.1016/j.amjmed.2018.12.011.

Article  PubMed  Google Scholar 

Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among US Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17. https://doi.org/10.15585/mmwr.mm7104a1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among US Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793–8. https://doi.org/10.15585/mmwr.mm7336a3.

Article  PubMed  PubMed Central  Google Scholar 

Loehr J (2024) Pneumococcal Vaccines [Presentation Slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https://stacks.cdc.gov/view/cdc/157883 June 27, 2024. Accessed October 1, 2024.

Kobayashi M (2024) Preliminary Work Group Interpretations of EtR and Next Steps: PCV-21 [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https://stacks.cdc.gov/view/cdc/157880/cdc_157880_DS1.pdf February 29, 2024. Accessed October 1, 2024.

Spach D (2024) National HIV Curriculum: Basic HIV Primary Care. Immunizations in Adults—Pneumococcal Vaccination. https://www.hiv.uw.edu/custom/primary-care/immunizations/11 2024. Accessed December 12, 2024

Garrido HMG, Schnyder JL, Tanck MWT, Vollaard A, Spijker R, Grobusch MP, et al. Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. EClinicalMedicine. 2020;29–30:100576. https://doi.org/10.1016/j.eclinm.2020.100576.

Article  PubMed  PubMed Central  Google Scholar 

Garcia Garrido HM, Schnyder JL, Haydari B, Vollaard AM, Tanck MWT, de Bree GJ, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy. Int J Antimicrob Agents. 2022;60(2):106629. https://doi.org/10.1016/j.ijantimicag.2022.106629.

Article  CAS  PubMed  Google Scholar 

Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022;36(3):373–82. https://doi.org/10.1097/qad.0000000000003126.

Article  CAS  PubMed  Google Scholar 

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7). ClinicalTrials.gov. NCT05393037. https://clinicaltrials.gov/study/NCT05393037 Updated July 25, 2024. Accessed August 12, 2024.

Rudmann KC, Cooper G, Marjuki H, Reingold A, Barnes M, Petit S, et al. Meningococcal Disease in Persons With HIV Reported Through Active Surveillance in the United States, 2009–2019. Open Forum Infect Dis. 2024;11(1):ofad696. https://doi.org/10.1093/ofid/ofad696.

Article  PubMed  PubMed Central  Google Scholar 

Harris CM, Wu HM, Li J, Hall HI, Lee A, Zell E, et al. Meningococcal Disease in Patients With Human Immunodeficiency Virus Infection: A Review of Cases Reported Through Active Surveillance in the United States, 2000–2008. Open Forum Infect Dis. 2016;3(4):ofw226. https://doi.org/10.1093/ofid/ofw226.

Article  PubMed  PubMed Central  Google Scholar 

Rubis AB, Howie RL, Marasini D, Sharma S, Marjuki H, McNamara LA. Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(24):663–4. https://doi.org/10.15585/mmwr.mm7224a4.

Article  PubMed  PubMed Central  Google Scholar 

Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases Report: Enhanced Meningococcal Disease Surveillance, 2022. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2022-508.pdf April 8, 2024. Accessed October 1, 2024.

Centers for Disease Control and Prevention. Health Alert Network Archive - 00505. Increase in Invasive Serogroup Y Meningococcal Disease in the United States. https://emergency.cdc.gov/han/2024/han00505.asp#:~:text=Based%20on%20updated%20surveillance%20data,who%20previously%20received%20MenACWY%20vaccine. Published March 28, 2024. Accessed October 1, 2024.

National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. . https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection Updated November 12, 2024. Accessed December 11, 2024.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161(4):676-81.e2. https://doi.org/10.1016/j.jpeds.2012.04.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isitt C, Bartolf A, Andrews N, Athaide S, Pryce-Williams R, Townsend-Payne K, et al. The propositive study: Immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV. HIV Med. 2023;24(9):979–89. https://doi.org/10.1111/hiv.13495.

Article  CAS  PubMed  Google Scholar 

Collins JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, Campos-Outcalt D, Loehr J, et al. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345–50. https://doi.org/10.15585/mmwr.mm7315a4.

Article  PubMed  PubMed Central  Google Scholar 

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults. ClinicalTrials.gov ID: NCT04502693. https://clinicaltrials.gov/study/NCT04502693 Updated March 5, 2024. Accessed August 12, 2024.

Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. https://doi.org/10.1016/s0140-6736(17)31449-6.

Article